Medi-Dose/EPS rolls out Steri-Tamp Tamper-Clear Syringe Seal
To complement its growing lines of IV and tamper-evident products, Medi-Dose/EPS is adding Steri-Tamp Tamper-Clear Syringe Seal to its lines of IV and tamper-evident products.
Officials at the Ivyland, Pa.-based company say that the Tamper-Clear Syringe Seal provides a tamper-evident seal with clear visibility of syringe graduations. They say that it is easily applied over the syringe cap and maintains the integrity of the medication and packaging–even when refrigerated. Once removed, the seal cannot be reapplied and removing the syringe cap destroys the seal.
Company executives add that the product is designed to withstand freezing temperatures down to -20 degrees centigrade and the product’s powerful adhesive seal has been shown to be more than three times stronger than others on the market. It provides a 100% sterile barrier. All Steri-Tamp products are packaged in a convenient USP 797 compliant dispenser.
“We’re always looking for ways to help pharmacists and nurses streamline their practices but maintain control and protection over the meds they dispense,” says Bob Braverman, director of marketing. “The new Tamper-Clear Syringe seal, as well as the rest of Steri-Tamp line of bag, vial and syringe seals, help practitioners accomplish this in a cost-effective manner. These products are an excellent addition to the fight against contamination, tampering and accidental double dosing.”
For more information on the EPS Steri-Tamp line of tamper-evident IV seals, visit MediDose.com, call 800-523-8966 or e-mail email@example.com.
Michigan Pharmacists Association, MedCerts partner to certify pharmacy technicians
LIVONIA, Mich. — Online healthcare and IT certification training school MedCerts is partnering with the Michigan Pharmacists Association for an effort that it says will bring higher-level training to pharmacy technicians. The partnership will offer state associations across the United States discounted access to online training for members to achieve certification goals, MedCerts said.
“We are excited to partner with the MedCerts team,” Michigan Pharmacists Association COO Dianne Malburg said. “Since 2009, MedCerts has had a strong track record of developing and delivering best-in-class training programs. This was reinforced in July when MedCerts earned nationally-recognized accreditation from the American Society of Health-System Pharmacists /Accreditation Council for Pharmacy Education for their Pharmacy Technician program. Our partnership will bring an innovative approach to technician training, and add significant value to other state associations.”
The partnership will bring discounts for the ASHP/ACPE accredited Pharmacy Technician Professional program and the Certified Pharmacy Technician program to state pharmacy associations around the country, the companies said. MedCerts said the goal is to increase the number of certified pharmacy technicians in the United States.
“We are very proud of our success in improving training initiatives in the Pharmacy industry,” MedCerts director of corporate development Domenic Policicchio said. “Our goal is simple: we want to broaden accessibility to technician training (ASHP/ACPE) and certify more technicians. This partnership brings an enormous amount of support and industry knowledge, with goals that align seamlessly. We are honored to be partnering with one of the most influential Associations in the country.”
Dynavax to introduce new hepatitis B vaccine
BERKELEY, Calif. — Dynavax Technologies last week announced that the U.S. Food and Drug Administration has approved Heplisav-B for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Heplisav-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
"Prevention of hepatitis B in adults through vaccination is more important than ever given the increase in the rate of infections," stated William Schaffner, professor of Preventive Medicine, Vanderbilt University Medical Center. "Too many at-risk adults remain unprotected against this virus. A two-dose schedule with higher rates of protection, along with other strategies, may help us move closer to the goal of eliminating hepatitis B as a public health problem in the United States."
Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States. There is no cure for hepatitis B, and infections are on the rise. In 2015, new cases of acute hepatitis B increased by more than 20% nationally.
"HEPLISAV-B is the first FDA-approved product for Dynavax and demonstrates our ability to develop innovative products and progress them from discovery to commercialization," added Eddie Gray, CEO Dynavax. "We expect that [Heplisav-B] will become an essential tool in the public health community's fight to prevent hepatitis B, and we look forward to making Heplisav-B available to clinicians and their adult patients."
Dynavax expects to commercially launch Heplisav-B in the United States in the first quarter of 2018. In preparation for launch, Dynavax has been building commercial infrastructure and optimizing manufacturing processes to meet anticipated demand.